Pharmaceutics
Cure8 research brief
Why This Matters
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people on IFX.
Who Should Pay Attention
Patients on infliximab or other anti-TNF therapy, gastroenterologists and IBD clinicians, clinical pharmacologists and researchers studying therapeutic-drug-monitoring and biomarkers for IBD.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study analyzed real-world data to see whether infliximab pharmacokinetics (specifically estimated drug clearance) and routine blood biomarkers can predict mucosal healing (MH) in people with inflammatory bowel disease.
The authors used population PK modeling (NONMEM) to estimate individual IFX clearance, correlated those parameters with endoscopic findings, and ran logistic regression and ROC analyses to identify predictors.
Key findings reported were that higher IFX clearance was associated with lower probability of achieving MH, and that leukocyte and platelet counts showed discriminatory ability; a combined model with IFX clearance and platelet count performed best in multivariable analysis.
The authors suggest that TDM-derived parameters together with simple blood tests could help reduce reliance on repeated endoscopies. This brief is grounded in the article abstract provided; Cure8 did not review the full paper beyond the source text supplied here.
Keep In Mind
This report is a single-center, retrospective real‑world study that used model-based estimates of IFX clearance rather than prospective randomized data. Findings should be confirmed in larger, multicenter or prospective studies before changing clinical practice.
Therapeutic-drug-monitoring methods and model implementations can vary between centers, which affects generalizability.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPharmaceutics
AuthorsAna Homšek, Marija Jovanović, Srđan Marković +5 more
InstitutionUniversity of Belgrade
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedSep 11, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study.
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
Pharmacometric Targets During Anti-TNF Induction and Their Association with Deep Remission in Pediatric Crohn’s Disease
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
Evaluation of pharmacokinetic metrics and pharmacodynamic biomarkers associated with endoscopic healing in pediatric Crohn's disease patients treated with anti-tumor necrosis factor biologics.
Identifies candidate drug‑level and immune biomarker cut‑points linked with endoscopic healing in pediatric Crohn's disease, which could help guide dosing or treatment changes if validated.